TY - JOUR
T1 - HER2-low prevalence among Hispanic/Latino women with breast cancer
T2 - A systematic review and meta-analysis
AU - Mendivelso-González, Daniel Felipe
AU - Cabezas, Daniel Clavijo
AU - Montoya, Luisa
AU - Vargas, Merideidy Plazas
AU - López-Correa, Patricia
AU - Colón, Eugenia
AU - Parra-Medina, Rafael
N1 - Publisher Copyright:
© 2024 Mendivelso-González et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2024/12
Y1 - 2024/12
N2 - Purpose HER2-low has garnered significant attention for the treatment of HER2-negative breast cancer. We aimed to determine the prevalence of HER2-low expression in Hispanic/Latino women with breast cancer (BC). Methods We searched in Embase, LILACS, and Medline databases for articles reporting the expression of HER2 immunohistochemistry with scores reported as 0, 1+, 2+, or 3+, with equivocal cases (2+) confirmed through in situ hybridization (ISH). Results A total of 12 articles were finally included, comprising 73,467 individuals. The prevalence of HER2-zero, HER2-low and HER2 positive cases among all BC (0, 1+, 2+/ISH-, 2+/ISH+ and 3+), was 45.0%, 32.0%, and 23.0%, respectively. The prevalence of HER2-zero and HER2-low expression among negative cases (0, 1+ and 2+/ISH-), was 53.0% and 47.0%, respectively. Conclusion There is an important percentage of Hispanic/Latino individuals who would benefit from HER2-targeted therapies, even in HER2 negative cases. Additional research on the prevalence of HER2-low tumors across a wider range of Latin American countries is required to better understand the molecular epidemiology of this biomarker within the Hispanic/Latino population.
AB - Purpose HER2-low has garnered significant attention for the treatment of HER2-negative breast cancer. We aimed to determine the prevalence of HER2-low expression in Hispanic/Latino women with breast cancer (BC). Methods We searched in Embase, LILACS, and Medline databases for articles reporting the expression of HER2 immunohistochemistry with scores reported as 0, 1+, 2+, or 3+, with equivocal cases (2+) confirmed through in situ hybridization (ISH). Results A total of 12 articles were finally included, comprising 73,467 individuals. The prevalence of HER2-zero, HER2-low and HER2 positive cases among all BC (0, 1+, 2+/ISH-, 2+/ISH+ and 3+), was 45.0%, 32.0%, and 23.0%, respectively. The prevalence of HER2-zero and HER2-low expression among negative cases (0, 1+ and 2+/ISH-), was 53.0% and 47.0%, respectively. Conclusion There is an important percentage of Hispanic/Latino individuals who would benefit from HER2-targeted therapies, even in HER2 negative cases. Additional research on the prevalence of HER2-low tumors across a wider range of Latin American countries is required to better understand the molecular epidemiology of this biomarker within the Hispanic/Latino population.
UR - http://www.scopus.com/inward/record.url?scp=85212399244&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0315287
DO - 10.1371/journal.pone.0315287
M3 - Article
C2 - 39666634
AN - SCOPUS:85212399244
SN - 1932-6203
VL - 19
JO - PLoS ONE
JF - PLoS ONE
IS - 12
M1 - e0315287
ER -
